Growth Company Investor Show

RNS Number : 4188T
Advanced Medical Solutions Grp PLC
05 June 2009

For Immediate Release

June 2009


Advanced Medical Solutions Group plc

(“AMS” or “the Company”)

To exhibit at Growth Company Investor Show on 10 June 2009

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that it will be exhibiting at the forthcoming Growth Company Investor Show to be held at the Barbican Exhibition Halls, London, on Wednesday 10 June 2009.

AMS will be represented by Don Evans, Chief Executive, and Chris Meredith, Group Commercial Director, on Stand No 68. 

The Company will also be making a formal presentation at 12:30 entitled “Healing Growth Pains with Seaweed, Silver and Superglue”.

Attendees at the show will be welcome to visit AMS’s stand and talk to the Company’s senior management about its growth strategy, along with having the opportunity to view some of the Company’s products.

The Growth Company Investor Show brings together leading small and mid-cap quoted companies giving existing and potential new investors the opportunity to meet and network with the companies’ management teams. Further details are available at


For further information, please contact:

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508 

Don Evans, Chief Executive

Mary Tavener, Finance Director

Buchanan Communications

Tel: +44 (0) 20 7466 5000

Mark Court / Stasa Filiplic

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.


The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market


AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

This information is provided by RNS
The company news service from the London Stock Exchange